Decoy Therapeutics Inc. (DCOY): Nasdaq/NYSE listing notice — Salarius Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00

Decoy Therapeutics Inc.

Nasdaq notified Salarius on Sept 5, 2023 that average closing bid price fell below $1.00 over prior 30 consecutive trading days.
Company has 180 calendar days (until March 4, 2024) to regain compliance by having bid price >= $1.00 for 10 consecutive business days.
If not compliant by March 4, 2024, Salarius may qualify for additional 180-day period if it meets other Nasdaq listing standards.
Company intends to monitor closing bid price and evaluate options to regain compliance; no immediate effect on listing or trading.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Decoy Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

September 5, 2023, Salarius Pharmaceuticals, Inc. (the “Company”) was notified (the “Notice”) by Nasdaq Stock Market, LLC (“Nasdaq”) that on September 1, 2023, the average closing price of the Company’s common stock (the “Common Stock”) over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing or trading of the Company’s common stock. In accordance with Nasdaq Listing Rule 581

View on SEC.gov

Browse all listing & compliance notices →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001615219-23-000067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.